TD Waterhouse Canada Inc. Grows Holdings in Eli Lilly and Company $LLY

TD Waterhouse Canada Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,737 shares of the company’s stock after buying an additional 3,899 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Eli Lilly and Company were worth $65,772,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $27,000. Financial Gravity Companies Inc. acquired a new position in Eli Lilly and Company in the second quarter worth about $31,000. Blume Capital Management Inc. increased its holdings in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the second quarter valued at approximately $35,000. Finally, TD Capital Management LLC raised its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.9%

Eli Lilly and Company stock opened at $1,030.49 on Wednesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,040.72. The company has a 50-day simple moving average of $838.20 and a 200-day simple moving average of $782.36. The firm has a market capitalization of $974.21 billion, a P/E ratio of 67.35, a P/E/G ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the business posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LLY. Daiwa Capital Markets boosted their price target on Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, November 3rd. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $886.00 to $1,104.00 in a report on Monday, November 10th. Berenberg Bank restated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, CICC Research boosted their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,020.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.